Hepatitis C Journal Articles

• Efficacy and Safety of Alfosbuvir Plus Daclatasvir in HCV This study investigated the efficacy and safety of oral alfosbuvir 400, 600 or 800 mg daily combined with 60 mg daily of daclatasvir for the treatment of HCV infection.
  Journal of Viral Hepatitis, August 09, 2022
• Liver Allocation Policy Change Impact on Donor Utilization How have the recent changes to the U.S. liver allocation policy impacted donor utilization?
  American Journal of Transplantation, August 03, 2022
• Lower Limit of Detection Required for HCV Viral Load Assay This study assessed the distribution of detectable viral loads 12 weeks following the end of treatment for HCV infection to inform the lower limit of detection of viral load assays for test of cure.
  Journal of Viral Hepatitis, August 02, 2022
• Tumor Size, Not Small Vessel Invasion, Predicts Survival in HCC This study reassessed the current tumor staging criteria for hepatocellular carcinoma, proposing a modification that tumor size, not small vessel invasion, more accurately predicts survival.
  American Journal of Clinical Pathology, July 28, 2022
• Identifiying HCV Patients Who May Be Cured in 4 Weeks Are soluble inflammatory mediators useful as biomarkers for prediction of a successful ultrashort antiviral treatment regimen for chronic HCV?
  Journal of Viral Hepatitis, July 26, 2022
• The "Netflix Model" for Hepatitis C Virus Therapies This paper describes the development and implementation of a novel subscription-based pricing model for HCV therapeutics, the Payer License Agreement.
  Liver International, July 26, 2022
• Factors Associated With COVID-19 Severity in People With HIV Learn more about the risk factors associated with COVID-19 severity among people living with HIV.
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, July 20, 2022
• Evaluating Effectiveness of Routine HBV and C Testing in an ED This study evaluated the real-world sustainability of an emergency department opt-out HCV and HBV testing program. Is opt-out ED testing practical in a large urban hospital setting?
  Journal of Viral Hepatitis, July 19, 2022
• HCV Eradication in HCC and Decreased Hepatic Functional Reserve Does DAA therapy after hepatocellular carcinoma treatment benefit patients with advanced-stage HCC or HCC with decompensated cirrhosis?
  Journal of Viral Hepatitis, July 12, 2022
• HCV Eradication Ameliorates the Prognosis of Advanced HCC According to this study, HCV eradication may not only improve liver function but also improve the prognosis of patients with HCV-related advanced HCC in patients treated with sorafenib.
  Journal of Viral Hepatitis, July 05, 2022
• Efficacy and Safety of DAA Therapy for HCV in Elderly Patients Is the efficacy of direct-acting antivirals, as measured by SVR, significantly different in patients 65 and older compared to younger patients?
  Journal of Viral Hepatitis, June 28, 2022
• Screening of Esophageal Varices in HCV+ Cirrhotic Patients This study aimed to evaluate the optimal type, frequency and length of surveillance of esophageal varices in HCV-positive cirrhotic patients who achieved SVR by direct-acting antivirals.
  Liver International, June 13, 2022
• Therapies for Managing Cirrhosis and its Complications This review outlines the currently available and emerging therapeutic options for the treatment of cirrhosis and its complications.
  Alimentary Pharmacology & Therapeutics, June 08, 2022
• Updated Histological Criteria of Autoimmune Hepatitis This consensus statement reviews the previous histological criteria of autoimmune hepatitis, and proposes updated criteria to be used for its diagnosis.
  Liver International, June 06, 2022
• Global Prevalence of Occult Hepatitis B A better understanding of the prevalence of occult HBV infection in the global population could lead to the development of better prevention and management strategies.
  Journal of Viral Hepatitis, May 30, 2022
• Association Between NAFLD and the Risk of Dementia The prevalence of both NAFLD and dementia is on the rise. Is there a link between the two?
  Liver International, May 30, 2022
• COVID-19 Impacts on Prevention and Care for HIV, Other STIs Restrictions imposed due to the COVID-19 pandemic have resulted in limited access to care and treatments. How have these delays impacted patients with HIV and other STIs?
  AIDS, May 27, 2022
• Genetic Factors in Sofosbuvir Treatment for Chronic HCV Are there patient-specific genetic factors that might help predict HCV patients likely to fail sofosbuvir treatment?
  Liver International, May 23, 2022
• Incidence and Mortality of HBV and HCV, Cirrhosis and HCC This article provides an update on the global incidence and mortality rates for these liver diseases. How have they changed in recent years?
  Journal of Viral Hepatitis, May 23, 2022
• Comorbidities and Co-Medications Among People With HIV How prevalent are comorbidities and the use of non-ART co-medications among people living with HIV?
  HIV Medicine, May 19, 2022